Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
| WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) - chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide) |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
| WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) - chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide) |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | No observations |
| WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) - chlorthalidone, chlorothiazide, indapamide (for hydrochlorothiazide) |